Dr Sheena Arora is a Research Fellow at CHERE. She is a health economist with expertise in applied economic evaluation focusing on child and caregiver health. Her PhD explored the economic implications of childhood intellectual disability. She has considerable experience working with large-scale studies, and has been involved in the design and implementation of trial based economic evaluations, including the design of data collection instruments, the application of linked data, costing of programs and evaluation of outcome data. She has conducted complex economic data analyses using advanced statistical methods, including the use of panel data techniques and the design and analysis of discrete choice experiments. Sheena also has considerable experience in the economic evaluation of pharmaceutical products and medical interventions through her work as an evaluator for the Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Can supervise: YES
- Policy and program evaluation
- Health technology assessment
- Economic evaluation
- Child and maternal health
Arora, S, Goodall, S, Viney, R & Einfeld, S 2020, 'Health-related quality of life among primary caregivers of children with intellectual disability', Journal of Intellectual Disability Research, vol. 64, no. 2, pp. 103-116.
Arora, S, Goodall, S, Viney, R & Einfled, S 2020, 'Societal cost of childhood intellectual disability in Australia', Journal of Intellectual Disability Research, vol. 64, no. 7, pp. 524-537.View/Download from: Publisher's site
Teague, SJ, Newman, LK, Tonge, BJ, Gray, KM, Aery, A, Andersson, E, Arciuli, J, Arora, S, Bezzina, L, Blackmore, R, Borland, R, Caruana, J, Cawood, D, Clarke, K, Day, J, Dossetor, D, Einfeld, S, Emerson, E, Evans, H, Fernandez, A, Goodall, S, Gray, KM, Haas, K, Henderson, K, Henry, T, Hinton, S, Hoath, F, Hodges, J, Horstead, S, Howlin, P, Hu, N, Keating, C, Kelly, E, Knott, R, Kotselas, P, Louie, E, McAuliffe, Z, O'Hagan, G, Panahi, B, Phillis, K, Rice, L, Rose, O, Rotolone, C, Salvador-Carulla, L, Sanders, M, Schoch, M, Shortt, F, Silove, N, Sofronoff, K, Stace, L, Taffe, J, Thompson, DM, Tonge, BJ, Viney, R & Wallman, E 2020, 'Attachment and child behaviour and emotional problems in autism spectrum disorder with intellectual disability', Journal of Applied Research in Intellectual Disabilities.View/Download from: Publisher's site
© 2019 John Wiley & Sons Ltd Background: Behaviour and emotional problems are highly prevalent in children with autism spectrum disorder (ASD). In typically developing children, attachment quality acts as a risk/protective factor for behavioural outcomes and adjustment, warranting investigation in children with ASD. Method: We investigated the relationship between attachment and child behaviour and emotional problems in children with ASD and comorbid intellectual disability. Data were collected from parent–child dyads where children were diagnosed with ASD and ID (n = 28) or other developmental disabilities (n = 20). Results: Children with ASD had higher levels of behaviour and emotional problems and more attachment difficulties than children with other developmental disabilities. Poorer attachment quality contributed uniquely to the variance in child behaviour and emotional problems. Conclusions: Interventions targeting behaviour and emotional problems in children with ASD may benefit from an attachment model which addresses the child's difficulty in using caregivers as a coregulatory agent of emotions.
Arora, S, Goodall, S, Viney, R & Einfeld, S 2019, 'Using discrete choice experiment methods to estimate the value of informal care: the case of children with intellectual disability', PharmacoEconomics, vol. 37, no. 4, pp. 501-511.View/Download from: Publisher's site
Teague, SJ, Newman, LK, Tonge, BJ & Gray, KM 2018, 'Caregiver Mental Health, Parenting Practices, and Perceptions of Child Attachment in Children with Autism Spectrum Disorder', JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, vol. 48, no. 8, pp. 2642-2652.View/Download from: Publisher's site
Butler, K, Reeve, R, Arora, S, Viney, R, Goodall, S, van Gool, K & Burns, L 2016, 'The hidden costs of drug and alcohol use in hospital emergency departments', Drug and Alcohol Review, vol. 35, no. 3, pp. 359-366.View/Download from: Publisher's site
Reeve, R, Arora, S, Butler, K, Viney, R, Burns, L, Goodall, S & van Gool, K 2016, 'Evaluating the impact of hospital based drug and alcohol consultation liaison services', Journal of Substance Abuse Treatment, vol. 68, pp. 36-45.View/Download from: Publisher's site
Arora, S, Roxburgh, A, Bruno, R, Nielsen, S & Burns, L 2013, 'A cross-sectional analysis of over-the-counter codeine use amongst an Australian sample of people who regularly inject drugs', Drug and Alcohol Review, vol. 32, no. 6, pp. 574-581.View/Download from: Publisher's site
Introduction and Aims. The study aims to examine the medical and non-medical use of over-the-counter (OTC) codeine combination drugs in a sample of people who inject drugs; and to examine risk factors associated with exceeding therecommended dose of OTC codeine, including the experience of pain. Design and Methods. This study analysed annual survey data from a convenience sample of people who inject drugs in Australia who are interviewed for the Illicit Drug Reporting System. People who have injected drugs (n = 902) on at least a monthly basis in the preceding six months across Australia were interviewed.Participants were asked about their use of OTC codeine and their experience of pain. Results. One third (35%) of participants had used OTC codeine in the preceding six months and 52% (95% confidence interval 48.755.3) of this group had exceeded the recommended dose on their last occasion of use.This clearly places them at increased risk of harms associated with toxicity from the accompanying analgesic found in combination codeine products. Multivariate analyses demonstrated that those exceeding the recommended codeine dose of OTC codeine were more likely to be experiencing moderate to very severe pain. Discussion and Conclusion. There is a need to evaluate the approach to pain management in this population. Greater pharmacist involvement, real-time monitoring of sales, the development of screening tools to identify those at risk of harm and further education of primary care practitioners could be beneficial in reducing the risk of harm associated with these medications for all users of OTC codeine, including people who inject drugs.
Arora, S 2019, 'Using DCE methods to estimate informal care', International Society for Pharmacoeconomics and Outcomes Research Women in Health Economics and Outcomes Research, Sydney.
Arora, S, Goodall, S, Viney, R & Einfeld, S 2017, 'The health-related quality of life of caregivers of children with intellectual disability [Conference Presentation]', 39th Annual Australian Health Economics Society Conference, Sydney.
Arora, S, Goodall, S, Einfeld, S & Viney, R 2016, 'Using Discrete Choice experiments to value informal care provided to children with intellectual disabilities', ISPOR 7th Asia-Pacific Conference, Singapore.
Arora, S, Goodall, S, Viney, R & Einfeld, S 2016, 'Using a discrete choice experiment to value informal care provided to children with intellectual disabilities', 38th Annual Australian Health Economics Society Conference, Perth.
Reeve, R, Butler, K, Burns, L, Viney, RC, Arora, S, Goodall, S & van Gool, K 2015, 'The costs and consequences of targeting AOD patients presenting to Hospital Emergency Departments', APSAD Annual Scientific Alcohol and Drug Conference, Perth.
Reeve, R, Arora, S, Viney, R, Goodall, S, van Gool, K, Knox, S & Kenny, PM NSW Health 2014, Evaluation of NSW Health Drug and Alcohol Consultation Liaison Services. Report for the Mental Health Drug and Alcohol Office (MHDAO), North Sydney.
Arora, S & Burns, L NDARC 2012, ACT trends in ecstasy and related drug markets 2011: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian Drug Trends Series No. 84, pp. 1-93, Sydney.
Arora, S & Burns, L NDARC 2012, Australian Capital Territory Drug Trends 2011. Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trend Series No. 75, pp. 1-88, Sydney.